insitro

SOUTH SAN FRANCISCO, Calif., October 06, 2026--insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained on mul

View original ↗

Share SOUTH SAN FRANCISCO, Calif. – October 6, 2026 – insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained

View original ↗

Share Last year, insitro and Eli Lilly and Company (Lilly) teamed up to build AI models that predict in vivo properties of small molecules, powered by the corpus of proprietary data that Lilly has accumulated over decades of R&D. Together, we built the in vivo PK model available in Lilly TuneLab as of October 6, to predict in vivo pharmacokinetics (PK) across four preclinical species: mouse, rat, dog, and monkey. Des

View original ↗

Share - Findings from insitro’s lead therapeutic CTRO-1013 program demonstrate that liver-targeted silencing of IRS1 lowered circulatory biomarkers associated with fibrosis progression and hepatocyte injury in an industry-standard fibrogenic preclinical mouse model of MASH - Data presented today at ADA provide converging evidence from human genetics and preclinical models supporting IRS1’s effect on liver fat and liv

View original ↗

Share Amyotrophic Lateral Sclerosis (ALS) presents one of the most formidable challenges in medical science. For too long, the search for effective treatments has been hampered by a temptation to revisit familiar hypotheses and established biological pathways. While understandable given the slow progress and frequent setbacks, this approach rarely advances the science. At the heart of insitro’s collaboration with Bri

View original ↗

Collaboration expands to include two additional therapeutic targets for the treatment of ALS discovered via insitro’s AI-driven Virtual Human™ platform Joint effort focuses on identifying key biological drivers to deliver disease-modifying interventions for ALS patients SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its stra

View original ↗

Share How insitro unlocked population-scale human genetics in a tissue that has resisted measurement for decades – and what it reveals about peripheral approaches to metabolic disease The Furnace We Couldn’t See The human body contains a type of fat tissue engineered to burn energy rather than store it. Brown adipose tissue – dense with mitochondria, rich in uncoupling proteins – converts glucose and lipids into heat

View original ↗

Share AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in preclinical models through peripheral adipose beiging, preserving lean mass Key findings presented at the Keystone Symposia on Obesity Therapeutics SOUTH SAN FRANCISCO, Calif. – Feb 2, 2026 – insitro, the AI therapeutics company built on causal biology, today repo

View original ↗

Share TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and oligonucleotide capabilities, unifying therapeutic design across all major drug modalities in a single AI engine SOUTH SAN FRANCISCO, Calif. – Jan. 12, 2026 – insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insi

View original ↗

Share The primary driver of clinical attrition in drug discovery is often not insufficient scientific rigor, it is misalignment between the biological target and the therapeutic intervention. Discovery organizations have historically structured themselves around technological capabilities, operating as either small molecule, biologics, or oligonucleotide specialists. This specialization creates an underappreciated co

View original ↗

insitro announced it will acquire CombinAbleAI and, alongside the deal, has launched TherML (Therapeutic Machine Learning), a platform it describes as a single, modality-agnostic AI engine for drug discovery and design. The deal is expected to close in late January 2026 and is intended to expand insitro’s capabilities beyond its existing small-molecule and oligonucleotide work into antibodies and other complex biolog

View original ↗

Share New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth to more rapidly identify novel therapeutic targets. SOUTH SAN FRANCISCO, Calif. — Dec. 16, 2025 — insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature

View original ↗